Triple combinations of antianginal preparations in the treatment of stable effort stenocardia in elderly and senile patients


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A prospective, randomized study of the efficacy and safety of antianginal therapy using combinations of bisoprolol, ivabradine and trimetazidine or ranolazine at the age 60 to 79 years included 107 patients with coronary artery disease and grade II/III stable effort angina. In case of retention of angina and/or painless myocardial ischemia against the background of use of bisoprolol and ivabradine after randomization, patients were additionally prescribed with trimetazidine (35 mg twice a day, n=54) or ranolazine (500 mg twice a day, n=53). Within 6 months, both methods of treatment were well tolerated, significantly improved the results of the treadmill tesT., the left ventricular systolic and diastolic functions, the structural and functional state of large arteries, and the quality of life of patients. Trimetazidine significantly reduced the duration of painless ST-segment depression according to Holter ECG monitoring. Combinations of low-dose ß-blocker with ivabradine and trimetazidine or ranolazine can be used in the treatment of refractory stable angina in elderly and senile patients.

全文:

受限制的访问

作者简介

S. Kanorsky

FSBEI HE “Kuban State Medical University" of RMH

Email: kanorskysg@mail.ru
MD, Prof., Head of the Department of Therapy № 2

N. Smolenskaya

FSBEI HE “Kuban State Medical University" of RMH

Department of Therapy № 2 of the Faculty of Advanced Training and Professional Retraining of Specialists

参考

  1. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603.
  2. Padala S.K., Lavelle M.P., Sidhu M.S., Cabral K.P., Morrone D., Boden W.E., Toth P.P. Antianginal Therapy for Stable Ischemic Heart Disease. J. Cardiovasc. Pharmacol. Ther. 2017 Jan 1. [Epub ahead of print].
  3. Kloner R.A., Chaitman B. Angina and Its Management. J. Cardiovasc. Pharmacol. Ther. 2017;22:199-209.
  4. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
  5. Chong C.R., Ong G.J., Horowitz J.D. Emerging drugs for the treatment of angina pectoris. Expert. Opin. Emerg. Drugs. 2016;21:365-76.
  6. Müller-Werdan U., Stöckl G., Ebelt H. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp. Gerontol. 2014; 59:34-41.
  7. Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F. 3rd, Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., Marino P., Oh J.K., Popescu B.A., Waggoner A.D. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016;29:277-314.
  8. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L., Spencer K.T., Tsang W., Voigt J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015;16:233-70.
  9. Wimmer N.J., Scirica B.M., Stone PH. The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: a review. Prog. Cardiovasc. Dis. 2013;56:195-202.
  10. Patel M.R., Calhoon J.H., Dehmer G.J., Grantham J.A., Maddox T.M., Maron D.J., Smith P.K. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2017;69:2212-41.
  11. Sedlis S.P., Hartigan P.M., Teo K.K., Maron D.J., Spertus J.A., Mancini G.B., Kostuk W., Chaitman B.R., Berman D., Lorin J.D., Dada M., Weintraub W.S., Boden W.E.; COURAGE Trial Investigators. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N. Engl. J. Med. 2015;373:1937-46.
  12. Windecker S., Kolh P.,Alfonso F., Collet J.P., Cremer J., Falk V., Filippatos G., Hamm C., Head S.J., Jüni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G.,NeumannFJ., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W., Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014;35:2541-619.
  13. Giannopoulos A.A.,Giannoglou G.D.,Chatzizisis Y.S. Pharmacological approaches of refractory angina. Pharmacol. Ther. 2016;163:118-31.
  14. Giannopoulos A.A.,Giannoglou G.D.,Chatzizisis Y.S. Refractory angina: new drugs on the block. Expert Rev. Cardiovasc. Ther. 2016;14:881-83.
  15. Fox K., Ford I., Steg P.G., Tardif J.C., Tendera M., Ferrari R.; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N. Engl. J. Med. 2014; 371:1091-99.
  16. Ibanez B., Raposeiras-Roubin S., Garcla-Ruiz J.M. The Swing of ß-Blockers: Time for a System Reboot. J. Am. Coll. Cardiol. 2017;69:2721-24.
  17. Dezsi C.A. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence. Am. J. Therapeutics 2016;23:e871-79.
  18. Wei J., Xu H., Shi L., Tong J., Zhang J. Trimetazidine protects cardiomyocytes against hypoxia-induced injury through ameliorates calcium homeostasis. Chem. Biol. Interact. 2015;236:47-56.
  19. Liu Z., Chen J.M., Huang H., Kuznicki M., Zheng S., Sun W., Quan N., Wang L., Yang H., Guo H.M., Li J., Zhuang J., Zhu P. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65:122-30.
  20. Yang Q., Yang K., Li A.Y. Trimetazidine protects against hypoxia-reperfusion-induced cardiomyocyte apoptosis by increasing microRNA-21 expression. Int. J. Clin. Exp. Pathol. 2015;8:3735-41.
  21. Rayner-Hartley E., Sedlak T. Ranolazine: A Contemporary Review. J. Am. Heart Assoc. 2016;5:e003196.
  22. Bairey Merz C.N., Handberg E.M., Shufelt C.L., Mehta P.K., Minissian M.B., Wei J., Thomson L.E., Berman D.S., Shaw L.J., Petersen J.W., Brown G.H., Anderson R.D., Shuster J.J., Cook-Wiens G., Rogatko A., Pepine C.J. A randomized, placebocontrolled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur. Heart J. 2016;37:1504-13.
  23. McCarthy C.P., Mullins K.V., Kerins D.M. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur. Heart J. Cardiovasc. Pharmacother. 2016;2:266-72.
  24. Zhao Y., Peng L., Luo Y., Li S., Zheng Z., Dong R., Zhu J., Liu J. Trimetazidine improves exercise tolerance in patients with ischemic heart disease: A meta-analysis. Herz. 2016;41:514-22.
  25. Gao D., Ning N., Niu X., Hao G., Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278-86.
  26. Salazar C.A., Basilio Flores J.E., Veramendi Espinoza L.E., Mejia Dolores J.W., Rey Rodriguez D.E., Loza Munarriz C. Ranolazine for stable angina pectoris. Cochrane Database Syst. Rev. 2017;2:CD011747.
  27. Bavry A.A., Park K.E., Choi C.Y, Mahmoud A.N., Wen X., Elgendy I.Y Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study). Cardiol. Ther. 2017;6:81-8.
  28. Weisz G., Genereux P., Ihiguez A., Zurakowski A., Shechter M., Alexander K.P., Dressler O., Osmukhina A., James S., Ohman E.M., Ben-Yehuda O., Farzaneh-Far R., Stone G.W.; RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:136-45.
  29. Fanaroff A.C., James S.K., Weisz G., Prather K., Anstrom K.J., Mark D.B., Ben-Yehuda O., Alexander K.P., Stone G.W., Ohman E.M. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. J. Am. Coll. Cardiol. 2017;69:2304-13.
  30. Xu X., Zhang W., Zhou Y., Zhao Y., Liu Y., Shi D., Zhou Z., Ma H., Wang Z., Yu M., Ma Q., Gao F., Shen H., Zhang J. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a singlecentre, prospective, randomized, double-blind study at 2-year follow-up. Clin. Drug Investig. 2014;34:251-58.
  31. Rehberger-Likozar A., Sebestjen M. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Coron. Artery Dis. 2015;26:651-56.
  32. Henry T.D., Satran D., Hodges J.S., Johnson R.K., Poulose A.K., Campbell A.R., Garberich R.F., Bart B.A., Olson R.E., Boisjolie C.R., Harvey K.L., Arndt T.L., Traverse J.H. Long-term survival in patients with refractory angina. Eur. Heart J. 2013;34:2683-88.
  33. Stone P.H. Ischemia dictates outcome, not symptoms. J. Am. Coll. Cardiol. 2013;61:712-13.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##